Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Rachelle Eusebio"'
Publikováno v:
Infectious Diseases in Obstetrics and Gynecology, Vol 10, Iss 3, Pp 141-151 (2002)
Objective: To assess differences in prevalence and cell densities of enterococci, Gram negative enterics (GNEs), yeast and Staphylococcus aureus among four genital sites and to examine whether the presence of organisms at one site affected the presen
Externí odkaz:
https://doaj.org/article/d22e087375894b9da7dd10d3687c0153
Autor:
Nicholas C A Claydon, Svetlana Farrell, Nikki Hellin, Rachelle Eusebio, Nicola X West, Tao He, Aneta Wilberg, Joon Seong, Emma L Macdonald
Publikováno v:
International Journal of Dental Hygiene
Objectives To assess the protective effects of a 0.454% stabilized stannous fluoride dentifrice and a marketed triclosan dentifrice against enamel erosion in a 10‐day in situ model. Methods This was a double‐blind, randomized, 2‐treatment, 4‐
Publikováno v:
The Journal of clinical dentistry. 28(4 Spec No)
The aim of this study was to compare the antibleeding/antigingivitis effectiveness of a newly formulated 0.454% stabilized stannous fluoride dentifrice and a marketed positive control triclosan-containing dentifrice in adults with mild-to-moderate gi
Autor:
Lynn R, Friesen, C R, Goyal, Jimmy G, Qaqish, Tao, He, Rachelle, Eusebio, Marianne, Zsiska, Teresa, Farmer, Eva, Schneiderman
Publikováno v:
The Journal of clinical dentistry. 28(4 Spec No)
To compare the effect of a stannous fluoride dentifrice versus a triclosan-containing dentifrice on the reduction of plaque using in vitro and clinical models.Both investigations evaluated a novel 0.454% stabilized stannous fluoride dentifrice (Crest
A Randomized Controlled Clinical Trial to Evaluate Extrinsic Stain Removal of a Whitening Dentifrice
Publikováno v:
The Journal of clinical dentistry. 27(4)
To evaluate the extrinsic stain removal efficacy of a new whitening dentifrice containing sodium hexametaphosphate (SHMP) over a two-week period.This study used a controlled and randomized, examiner-blind, single-center, two-treatment, parallel group
Autor:
Rachelle Eusebio, Roman S. Lorenc, Karen J. Stoner, Steven Boonen, Eric S. Orwoll, Dietrich Wenderoth
Publikováno v:
Bone. 51:383-388
A 2-year, randomized, double-blind, placebo-controlled study in men with osteoporosis demonstrated that treatment with risedronate 35mg once a week significantly decreased bone turnover markers (BTMs) and increased bone mineral density (BMD). This st
Autor:
Ellen Matzkin, Jose R. Zanchetta, Pierre D. Delmas, John F. Beary, Claude-Laurent Benhamou, Christian Roux, Steven Boonen, Rachelle Eusebio, Z. Man, Artur J. Racewicz, Michael R. McClung, David Ernest Burgio
Publikováno v:
Osteoporosis International
Summary: This study showed that risedronate 150-mg once a month provides similar efficacy and safety at 2 years compared with risedronate 5-mg daily for the treatment of postmenopausal osteoporosis. This adds to the range of risedronate dosing option
Autor:
Christian Roux, Ellen Matzkin, Rachelle Eusebio, Claude-Laurent Benhamou, Michael R. McClung, Z. Man, John F. Beary, Artur J. Racewicz, Pierre D. Delmas, David Ernest Burgio, Jose R. Zanchetta, Steven Boonen
Publikováno v:
Bone. 42:36-42
Introduction: Risedronate has been shown to be effective in the treatment of postmenopausal osteoporosis when given orally in daily or weekly doses or on 2 consecutive days per month. This randomized, double-blind, multi-center study was designed to
Autor:
Darrell A. Russell, Rachelle Eusebio, Karen A. Pallone Stevens, James H. Powell, William H. Barr, David Y. Mitchell, Gary A. Thompson, Frank P. Duke, John D. Nesbitt
Publikováno v:
Pharmaceutical Research. 18:166-170
Purpose. To determine the pharmacokinetics and absolute bioavailability of risedronate after single-dose oral administration of 30 mg risedronate as a tablet and an aqueous solution, and 0.3 mg risedronate as an intravenous infusion.
Autor:
S. C. Kelly, Rachelle Eusebio, Gary A. Thompson, David Y. Mitchell, Karen A. Pallone, John D. Nesbitt, J. V. St. Peter, Darrell A. Russell, James H. Powell
Publikováno v:
British Journal of Clinical Pharmacology. 49:215-222
Aims To determine the relationship between risedronate pharmacokinetics and renal function. Methods Risedronate was administered to adult men and women (n=21) with various degrees of renal function (creatinine clearance 15–126 ml min−1 ) as a sin